Forward-Looking Statements | --- | --- | --- | --- | --- | --- | |--------------|-------|-------|-------|-------|-------| | | | | | | | | REVANCE | | | | | | | Investor | | | | | | | Presentation | | | | | | | NASDAQ: RVNC | | | | | | | | | | | | | | March 2023 | | | | | | This presentation also contains estimates and other statistical data made by independent parties and by us relcling to nacket size and growth and other odata doubut our inc of assumptions and limitations, and you are coulioned not to give ...

Revance Therapeutics, Inc. (NASDAQ:RVNC) Q4 2022 Earnings Conference Call February 28, 2023 4:30 AM ET Company Participants Jessica Serra – Head of Investor Relations and ESG Mark Foley – Chief Executive Officer Dustin Sjuts – President Toby Schilke – Chief Financial Officer Conference Call Participants David Amsellem – Piper Sandler Annabel Samimy – Stifel Seamus Fernandez – Guggenheim Securities Stacy Ku – Cowen Balaji Prasad – Barclays Lachlan Hanbury-Brown – William Blair Terence Flynn – Morgan Stanley ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File No. 001-36297 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 77-0551645 State or other juris ...

Revance Therapeutics, Inc. (NASDAQ:RVNC) Q3 2022 Results Conference Call November 8, 2022 4:30 PM ET Company Participants Jessica Serra - Head of Investor Relations & ESG Mark Foley - Chief Executive Officer Dustin Sjuts - President Tobin Schilke - Chief Financial Officer & Principal Accounting Officer Conference Call Participants Chris Shibutani - Goldman Sachs Ken Cacciatore - Cowen David Amsellem - Piper Sandler Stacy Lee - Stifel Justin Phillips - Morgan Stanley Rohit Bhasin - Needham & Company Operator ...

Financial Data and Key Metrics Changes - Total revenue for Q2 2022 increased by 51% year-over-year to $28.4 million, primarily driven by increased sales of the RHA Collection [28] - RHA sales in Q2 totaled $25.5 million, a 50% increase year-over-year, bringing first half 2022 RHA sales to $46.3 million [17][28] - Non-GAAP operating expenses for Q2 were $62.0 million, an 8% decline compared to the same period last year [29] Business Line Data and Key Metrics Changes - The RHA Collection achieved its best quarter to date, with significant account growth across fillers and the OPUL platform [5] - Gross processing volume (GPV) for OPUL in Q2 was $166 million, up 23.2% year-over-year, with a trailing 12-month GPV exceeding $600 million [23] Market Data and Key Metrics Changes - The U.S. facial injectables market is projected to grow at a compound annual growth rate of 8% to reach $4.7 billion by 2026 [11] - The market for muscle movement disorders is expected to grow from $900 million to $1.4 billion in the U.S. by 2026 [16] Company Strategy and Development Direction - The company is focused on launching DaxibotulinumtoxinA for Injection, which is expected to expand access to the U.S. facial injectables market valued at $3.2 billion [10] - The strategy includes a differentiated go-to-market approach targeting the prestige segment and leveraging new product innovations [14] Management's Comments on Operating Environment and Future Outlook - Management has not observed significant impacts from macroeconomic factors on consumer spending, maintaining confidence in the resilience of the facial injectables market [13] - The company remains optimistic about the growth of its base business and expanding product lines, pending approval of DaxibotulinumtoxinA [16] Other Important Information - The FDA completed its inspection of the manufacturing facility, with corrective actions from previous observations considered closed [8] - The company has a cash runway into 2024, with total cash and equivalents of $233.8 million as of June 30, 2022 [31] Q&A Session Summary Question: Insights on FDA observations and PDUFA date - Management expressed satisfaction with closing previous observations and confidence in addressing new ones, anticipating a response by the PDUFA date of September 8 [40][41] Question: Differences in DaxibotulinumtoxinA's spreading dynamics - Management noted that DaxibotulinumtoxinA has a unique formulation that may lead to different spreading characteristics compared to existing products, with positive feedback from clinical trials [43][44] Question: Rollout strategy for DaxibotulinumtoxinA - The rollout will focus on training and integrating practices, targeting top accounts in the prestige segment, with a significant emphasis on clinical outcomes [50][56] Question: Market reception and pricing strategy - Management believes the unique value proposition of DaxibotulinumtoxinA will resonate well with consumers and practices, maintaining a premium pricing strategy [58][86] Question: Future therapeutic indications - The company plans to focus on cervical dystonia first before considering other therapeutic indications, with a commitment to advancing its pipeline based on market conditions [87]

PART I. FINANCIAL INFORMATION [Condensed Consolidated Financial Statements (Unaudited)](index=3&type=section&id=Item%201.%20Condensed%20Consolidated%20Financial%20Statements%20(Unaudited)) The unaudited condensed consolidated financial statements for the period ended June 30, 2022, reveal a significant net loss and accumulated deficit, with management expressing substantial doubt about the company's ability to continue as a going concern due to delayed product approval - The company's ability to continue as a going concern is in **substantial doubt** due to insufficient capital to fund operations for at least 12 months, primarily stemming from the delayed commercial launch of **DaxibotulinumtoxinA for Injection** following the FDA's Complete Response Letter (CRL)[25](index=25&type=chunk) Condensed Consolidated Statements of Operations (in thousands) | Metric | Three Months Ended June 30, 2022 | Three Months Ended June 30, 2021 | Six Months Ended June 30, 2022 | Six Months Ended June 30, 2021 | | :--- | :--- | :--- | :--- | :--- | | **Total Revenue** | $28,368 | $18,804 | $53,629 | $32,103 | | **Loss from Operations** | $(57,842) | $(70,337) | $(120,063) | $(140,349) | | **Net Loss** | $(61,435) | $(72,197) | $(125,777) | $(143,836) | | **Net Loss Per Share** | $(0.88) | $(1.07) | $(1.82) | $(2.15) | Condensed Consolidated Balance Sheet Highlights (in thousands) | Metric | June 30, 2022 | December 31, 2021 | | :--- | :--- | :--- | | Cash and cash equivalents | $69,418 | $110,623 | | Short-term investments | $164,397 | $114,448 | | **Total Assets** | **$561,883** | **$531,163** | | **Total Liabilities** | **$564,514** | **$462,692** | | **Total Stockholders' Equity (Deficit)** | **$(2,631)** | **$68,471** | Condensed Consolidated Statements of Cash Flows (in thousands) | Cash Flow Activity | Six Months Ended June 30, 2022 | Six Months Ended June 30, 2021 | | :--- | :--- | :--- | | Net cash used in operating activities | $(105,495) | $(123,760) | | Net cash used in investing activities | $(61,313) | $(74,113) | | Net cash provided by financing activities | $126,478 | $31,956 | | **Net Decrease in Cash** | **$(40,330)** | **$(165,917)** | [Notes to Condensed Consolidated Financial Statements](index=9&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) These notes provide details on accounting policies, revenue recognition, debt instruments, and contingencies, including a 'going concern' warning, new debt issuance, and ongoing legal proceedings - The company is involved in two significant legal cases: a **patent infringement lawsuit** by Allergan regarding **DaxibotulinumtoxinA for Injection**, and a **securities class action complaint** alleging misleading statements on manufacturing and regulatory approval timing[134](index=134&type=chunk)[137](index=137&type=chunk) - In March 2022, the company issued **$100.0 million** in notes under a Note Purchase Agreement with Athyrium, with an additional **$100.0 million** available upon FDA approval of **DaxibotulinumtoxinA for Injection** for glabellar lines[93](index=93&type=chunk) Revenue by Segment (in thousands) | Segment | Three Months Ended June 30, 2022 | Six Months Ended June 30, 2022 | | :--- | :--- | :--- | | Product Segment | $27,142 | $51,547 | | Service Segment | $1,226 | $2,082 | | **Total Revenue** | **$28,368** | **$53,629** | Loss from Operations by Segment (in thousands) | Segment | Three Months Ended June 30, 2022 | Six Months Ended June 30, 2022 | | :--- | :--- | :--- | | Product Segment | $(24,969) | $(49,920) | | Service Segment | $(5,598) | $(9,533) | | Corporate and other expenses | $(27,275) | $(60,610) | | **Total Loss from Operations** | **$(57,842)** | **$(120,063)** | [Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A)](index=30&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses financial performance, revenue growth driven by **RHA® Collection** sales, ongoing 'going concern' doubts, recent FDA regulatory updates, and capital preservation strategies - The FDA issued a **Form 483** with three observations following a July 2022 reinspection of the manufacturing facility, primarily related to SOP deviations and BLA documentation, to which the company has responded[163](index=163&type=chunk)[164](index=164&type=chunk)[165](index=165&type=chunk) - The company implemented **cost preservation measures**, including pausing non-critical hires and deferring the Phase 3 clinical program for upper limb spasticity, due to the delayed approval of **DaxibotulinumtoxinA**[173](index=173&type=chunk) Revenue Comparison (in thousands) | Revenue Type | Six Months Ended June 30, 2022 | Six Months Ended June 30, 2021 | Change | % Change | | :--- | :--- | :--- | :--- | :--- | | Product revenue | $46,320 | $28,686 | $17,634 | 61% | | Collaboration revenue | $5,227 | $2,905 | $2,322 | 80% | | Service revenue | $2,082 | $512 | $1,570 | 307% | | **Total revenue** | **$53,629** | **$32,103** | **$21,526** | **67%** | - The company generated **$31.6 million** in net proceeds from selling **1,734,853 shares** under its 2020 ATM Agreement, and established a new **$150.0 million** ATM agreement in May 2022 with no shares sold to date[170](index=170&type=chunk)[171](index=171&type=chunk) [Quantitative and Qualitative Disclosures about Market Risk](index=49&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20about%20Market%20Risk) The company's market risk exposure, primarily from foreign currency and interest rate fluctuations, has not materially changed since year-end 2021 - No material changes occurred in the company's market risk exposure for the six months ended June 30, 2022, compared to the 2021 Annual Report on Form 10-K disclosures[265](index=265&type=chunk) [Controls and Procedures](index=50&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective as of June 30, 2022, with no material changes to internal control over financial reporting - The principal executive and financial officers concluded that the company's disclosure controls and procedures were **effective** as of June 30, 2022[266](index=266&type=chunk) - No changes in internal control over financial reporting occurred during the quarter that materially affected, or are reasonably likely to materially affect, these controls[267](index=267&type=chunk) PART II. OTHER INFORMATION [Legal Proceedings](index=51&type=section&id=Item%201.%20Legal%20Proceedings) The company is involved in two significant legal matters: a patent infringement lawsuit by Allergan and a securities class action complaint - Allergan filed a **patent infringement complaint** against Revance concerning **DaxibotulinumtoxinA for Injection** and its manufacturing process, with Revance's motion to dismiss denied in July 2022[270](index=270&type=chunk) - A **securities class action complaint** alleges false or misleading statements by the company and officers regarding **DaxibotulinumtoxinA for Injection** manufacturing and regulatory approval timelines between November 2019 and October 2021[271](index=271&type=chunk) [Risk Factors](index=51&type=section&id=Item%201A.%20Risk%20Factors) This section outlines numerous risks, including substantial dependence on key products, 'going concern' doubts, regulatory challenges, intense competition, and intellectual property litigation - The company's future is substantially dependent on the clinical and commercial success of **DaxibotulinumtoxinA for Injection** and the **RHA® Collection** of dermal fillers, with regulatory approval for the former delayed[277](index=277&type=chunk)[281](index=281&type=chunk) - Substantial doubt exists about the company's ability to continue as a **going concern**, as existing capital is insufficient for the next 12 months, requiring FDA approval for **DaxibotulinumtoxinA** and additional funding for viability[287](index=287&type=chunk) - The company faces **significant competition** from large, established companies with greater financial and marketing resources, potentially developing safer, more effective, or less expensive products[363](index=363&type=chunk) - Ongoing **patent infringement litigation** with Allergan could be expensive, time-consuming, and potentially delay or prevent the commercialization of **DaxibotulinumtoxinA for Injection** if unsuccessful[403](index=403&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=98&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) No unregistered sales of equity securities occurred during the reporting period - None [Defaults Upon Senior Securities](index=98&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) No defaults upon senior securities were reported during the period - None [Other Information](index=98&type=section&id=Item%205.%20Other%20Information) No other information is reported for the period - None [Exhibits](index=99&type=section&id=Item%206.%20Exhibits) This section lists exhibits filed with Form 10-Q, including corporate governance documents, debt agreements, officer certifications, and XBRL data files

Revance Therapeutics, Inc. (NASDAQ:RVNC) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Jessica Serra – Head-Investor Relations and ESG Mark Foley – Chief Executive Officer Dustin Sjuts – President Toby Schilke – Chief Financial Officer Conference Call Participants Ken Cacciatore – Cowen and Co Seamus Fernandez – Guggenheim David Amsellem – Piper Sander Annabel Samimy – Stifel Balaji Prasad – Barclays Vamil Divan – Mizuho Securities Douglas Tsao – H.C. Wainwright Rohit Bhasin ...

PART I. FINANCIAL INFORMATION This section presents the company's unaudited condensed consolidated financial statements and management's discussion and analysis for the period [Item 1. Condensed Consolidated Financial Statements (Unaudited)](index=3&type=section&id=Item%201.%20Condensed%20Consolidated%20Financial%20Statements%20%28Unaudited%29) This section presents the unaudited condensed consolidated financial statements, including the balance sheets, statements of operations and comprehensive loss, statements of stockholders' equity, and statements of cash flows, along with detailed notes explaining significant accounting policies, revenue recognition, financial instruments, debt, equity, commitments, contingencies, and segment information for the period ended March 31, 2022 [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) This section presents the company's financial position, detailing assets, liabilities, and equity at specific reporting dates | Metric | March 31, 2022 (in thousands) | December 31, 2021 (in thousands) | | :-------------------------------- | :----------------------------- | :----------------------------- | | Total Assets | $639,546 | $531,163 | | Total Liabilities | $614,005 | $462,692 | | Total Stockholders' Equity | $25,541 | $68,471 | | Cash and cash equivalents | $198,359 | $110,623 | | Short-term investments | $64,231 | $114,448 | | Total current assets | $285,330 | $246,117 | | Total current liabilities | $71,066 | $67,289 | [Condensed Consolidated Statements of Operations and Comprehensive Loss](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) This section outlines the company's revenues, expenses, and net loss over the reporting periods | Metric | 3 Months Ended March 31, 2022 (in thousands) | 3 Months Ended March 31, 2021 (in thousands) | Change (in thousands) | % Change | | :------------------------------------------ | :------------------------------------------ | :------------------------------------------ | :------------------- | :------- | | Total Revenue | $25,261 | $13,299 | $11,962 | 90.0% | | Product revenue | $20,837 | $11,647 | $9,190 | 78.9% | | Collaboration revenue | $3,568 | $1,511 | $2,057 | 136.1% | | Service revenue | $856 | $141 | $715 | 507.1% | | Total operating expenses | $87,482 | $83,311 | $4,171 | 5.0% | | Loss from operations | $(62,221) | $(70,012) | $7,791 | (11.1)% | | Net loss | $(64,342) | $(71,639) | $7,297 | (10.2)% | | Basic and diluted net loss per share | $(0.94) | $(1.08) | $0.14 | (13.0)% | [Condensed Consolidated Statements of Stockholders' Equity](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Stockholders%27%20Equity) This section details changes in the company's equity, including additional paid-in capital and accumulated deficit | Metric | March 31, 2022 (in thousands) | December 31, 2021 (in thousands) | | :-------------------------------- | :----------------------------- | :----------------------------- | | Total Stockholders' Equity | $25,541 | $68,471 | | Additional paid-in capital | $1,487,822 | $1,466,369 | | Accumulated deficit | $(1,462,294) | $(1,397,952) | [Condensed Consolidated Statements of Cash Flows](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) This section summarizes the cash inflows and outflows from operating, investing, and financing activities | Metric | 3 Months Ended March 31, 2022 (in thousands) | 3 Months Ended March 31, 2021 (in thousands) | | :------------------------------------ | :------------------------------------------ | :------------------------------------------ | | Net cash used in operating activities | $(61,270) | $(74,755) | | Net cash provided by (used in) investing activities | $44,568 | $(38,420) | | Net cash provided by financing activities | $105,313 | $29,044 | | Net increase (decrease) in cash, cash equivalents, and restricted cash | $88,611 | $(84,131) | [Notes to Condensed Consolidated Financial Statements](index=8&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) This section provides detailed explanations and disclosures supporting the condensed consolidated financial statements - The company incurred a net loss of **$64.3 million** for the three months ended March 31, 2022, and has an accumulated deficit of **$1.5 billion**, raising substantial doubt about its ability to continue as a going concern[21](index=21&type=chunk)[22](index=22&type=chunk) - The FDA issued a Complete Response Letter (CRL) for DaxibotulinumtoxinA for Injection BLA due to manufacturing facility deficiencies, delaying commercial launch[22](index=22&type=chunk) - To mitigate going concern doubt, the company needs to execute its commercial strategy for RHA® Collection, obtain FDA approval for DaxibotulinumtoxinA for Injection to draw on the Second Tranche of debt, and raise additional capital[25](index=25&type=chunk) [1. The Company and Summary of Significant Accounting Policies](index=8&type=section&id=Note%201.%20The%20Company%20and%20Summary%20of%20Significant%20Accounting%20Policies) This note describes the company's business and outlines its significant accounting policies - Revance is a commercial-stage biotechnology company focused on DaxibotulinumtoxinA for Injection, RHA® Collection of dermal fillers, and the OPUL™ Relational Commerce Platform[20](index=20&type=chunk) - The company reported a net loss of **$64.3 million** for the three months ended March 31, 2022, and an accumulated deficit of **$1.5 billion**[21](index=21&type=chunk) - The FDA issued a Complete Response Letter (CRL) for DaxibotulinumtoxinA for Injection BLA due to manufacturing facility deficiencies, leading to a delay in commercial launch and raising substantial doubt about the company's ability to continue as a going concern. The BLA was resubmitted in March 2022 and accepted as a Class 2 resubmission with a PDUFA date of September 8, 2022, requiring a reinspection[22](index=22&type=chunk)[33](index=33&type=chunk) [2. Revenue](index=11&type=section&id=Note%202.%20Revenue) This note details the company's revenue recognition policies and disaggregates revenue by type | Revenue Type | 3 Months Ended March 31, 2022 (in thousands) | 3 Months Ended March 31, 2021 (in thousands) | | :-------------------- | :------------------------------------------ | :------------------------------------------ | | Product Revenue | $20,837 | $11,647 | | Collaboration Revenue | $3,568 | $1,511 | | Service Revenue | $856 | $141 | | Total Revenue | $25,261 | $13,299 | - All product revenue was generated from the sale of the RHA® Collection of dermal fillers[43](index=43&type=chunk) - Collaboration revenue increased due to increased development activities for the onabotulinumtoxinA biosimilar program with Viatris[51](index=51&type=chunk) - Service revenue increased primarily due to the commercial launch of OPUL™ in October 2021 and a change to gross accounting presentation of revenue[58](index=58&type=chunk) [3. Cash Equivalents and Short-Term Investments](index=14&type=section&id=Note%203.%20Cash%20Equivalents%20and%20Short-Term%20Investments) This note provides a breakdown of cash equivalents and short-term investments by category and fair value | Category | March 31, 2022 (Fair Value, in thousands) | December 31, 2021 (Fair Value, in thousands) | | :--------------------------------------- | :--------------------------------------- | :--------------------------------------- | | Money market funds | $166,585 | $90,355 | | Commercial paper | $34,464 | $87,964 | | U.S. treasury securities | $16,021 | $0 | | Corporate bonds | $13,746 | $26,484 | | Total cash equivalents and available-for-sale securities | $230,816 | $204,803 | [4. Intangible Assets, net](index=15&type=section&id=Note%204.%20Intangible%20Assets%2C%20net) This note presents the net carrying amount of intangible assets and related amortization expense | Category | March 31, 2022 (Net Carrying Amount, in thousands) | December 31, 2021 (Net Carrying Amount, in thousands) | Weighted Average Remaining Useful Lives (in years) | | :---------------------- | :------------------------------------------ | :------------------------------------------ | :------------------------------------------ | | Distribution rights | $17,514 | $19,535 | 2.2 | | Developed technology | $27,656 | $29,147 | 4.6 | | Customer relationships | $6,008 | $6,652 | 2.3 |

Financial Data and Key Metrics Changes - Revenue for Q4 2021 was $26.0 million, compared to $11.1 million in Q4 2020, representing a significant increase [25] - Full year 2021 revenue reached $77.8 million, up from $15.3 million in 2020, driven primarily by increased sales of the RHA collection of dermal fillers [25][26] - Operating expenses for Q4 2021 were $87.6 million, and for the full year, they totaled $352.5 million, excluding depreciation and amortization [27] Business Line Data and Key Metrics Changes - RHA collection sales for 2021 totaled $70.8 million, with Q4 sales reaching $23.8 million, a 138% increase over the first launch quarter [18][19] - The FinTech platform generated $0.5 million in service revenue for Q4 2021 and $1.3 million for the full year [26] Market Data and Key Metrics Changes - The gross payment volume (GPV) for the FinTech platform was $506 million for the full year 2021, with a run rate nearly tripling to almost $600 million by year-end [23][24] - The company has over 3,000 accounts in the US across its dermal filler and FinTech platform, generating over $0.5 billion in gross payment volume for the year [8] Company Strategy and Development Direction - The primary goal for 2022 is to gain FDA approval for DaxibotulinumtoxinA for injection in glabellar lines, which is expected to accelerate growth in aesthetics [17] - The company plans to drive top-line growth anchored by the RHA collection and deepen penetration of the OPUL relational commerce platform [17] - Capital allocation will focus on obtaining FDA approval, driving top-line growth, and investing in people and culture [27] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the regulatory path for DaxibotulinumtoxinA, highlighting progress in manufacturing and qualification activities [10][11] - The company remains focused on innovation and customer engagement despite challenges posed by the COVID-19 pandemic [15] Other Important Information - Cash, cash equivalents, and short-term investments as of December 31, 2021, were $225.1 million, sufficient to fund operations into 2023 [30] - The company has paused non-critical hires and deferred certain clinical programs to conserve cash [28] Q&A Session Summary Question: Timing of the refiling - Management indicated that the timing for the refiling of the BLA is more administrative at this point, with a focus on completing necessary documentation [37] Question: Financing options beyond 2023 - Management stated that they have sufficient cash to fund operations into 2023 and are considering various financing strategies to extend the cash runway [43] Question: Incremental sales from RHA Redensity - Management expressed excitement about RHA Redensity's approval, viewing it as a unique opportunity to enhance their product portfolio [50] Question: Market share potential in the US - Management noted that their current market share is trending towards high single-digit penetration and expressed confidence in future growth opportunities [52] Question: Impact of DaxibotulinumtoxinA on OPUL platform - Management believes that DaxibotulinumtoxinA will positively impact the OPUL platform, but each product has standalone value [77]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File No. 001-36297 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 77-0551645 State or other juris ...